3.10Open3.10Pre Close0 Volume12 Open Interest5.00Strike Price0.00Turnover458.63%IV-1.06%PremiumAug 16, 2024Expiry Date3.12Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5816Delta0.1734Gamma0.54Leverage Ratio-0.0172Theta-0.0024Rho-0.31Eff Leverage0.0019Vega
Tempest Therapeutics Stock Discussion
Tempest Therapeutics, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker TPST, is poised to release new data from its global randomized Phase 1b/2 combination study involving amezalpat (TPST-1120) in conjunction with atezolizumab and bevacizumab. This ...
No comment yet